Candel Therapeutics, Inc. (CADL), Tuesday, announced the publication of Phase 1b clinical trial results for CAN-2409 in newly diagnosed high-grade glioma in the journal Neuro-Oncology.
The phase 1b clinical trial evaluated the safety and tolerability of the combination of CAN-2409 and Nivolumab plus standard of care in newly diagnosed high-grade glioma patients.
The study demonstrated encouraging survival benefits and immune activation. The trial enrolled 41 patients, with a subset showing notable improvements.
Patients with MGMT-methylated tumors who underwent total tumor resection had a median overall survival of 30.6 months. CAN-2409 treatment induced systemic immune activation, enhancing T-cell diversity and reducing immunosuppressive cells.
Although CAN-2409 is not currently being developed for high-grade glioma due to portfolio prioritization, these findings support CAN-2409's potential as a pan-solid tumor therapy, noted the company.
CAN-2409 is currently in late-stage trials for prostate cancer, pancreatic ductal adenocarcinoma, and non-small cell lung cancer.
CADL is currently trading at $5.62 down $0.03 or 0.53 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.